<DOC>
	<DOCNO>NCT01469169</DOCNO>
	<brief_summary>This study investigate efficacy , safety , Pharmacokinetics ( PK ) Inhaled Iloprost ( Ventavis ) therapy Japanese pulmonary arterial hypertension ( PAH ) patient Main Treatment Phase ( 12 week ) investigate safety , tolerability , efficacy longterm Inhaled Iloprost ( Ventavis ) therapy Japanese PAH patient Extension Phase .</brief_summary>
	<brief_title>Inhaled Iloprost ( Ventavis ) : Efficacy , Safety , Pharmacokinetics ( PK ) Confirmation Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Male female subject age 18 75 year Symptomatic Pulmonary Artery Hypertension ( PAH ) classify ( Dana Point Classification 1 ) New York Heart Association ( NYHA ) /World Health Organization ( WHO ) functional class III IV PAPmean rest &gt; 25 mm Hg , Pulmonary capillary wedge pressure ( PCWP ) leave ventricular enddiastolic pressure &lt; /= 15 mm Hg Pulmonary Vascular resistance ( PVR ) &gt; /= 240 dyn.sec.cm5 ( &gt; /= 400 dyn.sec.cm5 patient treat endothelin receptor antagonist ( ERA ) phosphodiesterase5 inhibitor ( PDE5i ) ) measure Right Heart Catheter test Women childbearing potential men must agree use adequate contraception sexually active Baseline 6minute walk distance le 100 meter 500 meter Subjects critical severe PAH Forced Expiratory Volume 1 second ( FEV1 ) /Forced Vital Capacity ( FVC ) ratio &lt; 60 % and/or Total Lung Capacity ( TLC ) &lt; 70 % predict ( especially interstitial lung disease , TLC &lt; 60 % predict ) Clinically relevant obstructive lung disease ( e.g . asthma chronic obstructive pulmonary disease ) More mild patchy interstitial lung disease High Resolution Computerized Tomography ( HRCT ) History leftsided heart disease Uncontrolled systemic hypertension evidence systolic blood pressure &gt; /= 160 mm Hg diastolic blood pressure &gt; /= 100 mm Hg repeat measurement Systemic hypotension systolic blood pressure &lt; 85 mm Hg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Iloprost</keyword>
	<keyword>Inhalation</keyword>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Pulmonary Artery Hypertension</keyword>
	<keyword>Japanese Patients</keyword>
</DOC>